WANY
CRSP icon

Wealthspire Advisors (New York)’s CRISPR Therapeutics CRSP Stock Holding History

Wealthspire Advisors (New York)’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-854
Closed -$55.3K – 1435
2025
Q3 		$55.3K Buy
+854
New +$49K ﹤0.01% 1209

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
GP
GSK plc London $599M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wealthspire Advisors (New York)'s CRSP Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of CRISPR Therapeutics (CRSP) in Q4 2025, closing a stake of 854 shares — an estimated $55.3K sold.

Wealthspire Advisors (New York) first reported a position in CRSP in Q3 2025 and held it in 1 quarter. The position peaked at $55.3K in Q3 2025. 480 funds tracked by Wall St. Rank hold CRSP as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining CRISPR Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 854 CRISPR Therapeutics shares in Q4 2025, an estimated $55.3K.
  • Wealthspire Advisors (New York) first reported a position in CRISPR Therapeutics in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s CRISPR Therapeutics position peaked at $55.3K in Q3 2025.
  • 480 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.